Relmada Therapeutics, Inc. - Common Stock (RLMD)
3.0100
-0.6000 (-16.62%)
NASDAQ · Last Trade: Nov 17th, 4:09 PM EST
Detailed Quote
| Previous Close | 3.610 |
|---|---|
| Open | 3.550 |
| Bid | 3.010 |
| Ask | 3.020 |
| Day's Range | 2.980 - 3.600 |
| 52 Week Range | 3.070 - 8.000 |
| Volume | 1,854,357 |
| Market Cap | 52.59M |
| PE Ratio (TTM) | -4.068 |
| EPS (TTM) | -0.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,734,061 |
Chart
About Relmada Therapeutics, Inc. - Common Stock (RLMD)
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for pain and related disorders. The company is dedicated to addressing unmet medical needs through its advanced therapeutic candidates, which aim to provide safe and effective alternatives to existing pain management options. By leveraging its expertise in neuroscience and pharmacology, Relmada Therapeutics is working towards advancing novel therapies that enhance the quality of life for patients suffering from chronic pain conditions and other neurological issues. Read More
News & Press Releases
Management highlighted a clean safety record and cash runway through 2029.
Via The Motley Fool · November 13, 2026
Relmada Therapeutics (NASDAQ:RLMD) expects to submit applications for its bladder cancer treatment candidate NDV-01 and Prader-Willi syndrome program sepranolone by the end of 2026, executives said on the company’s third-quarter earnings call.
Chief Executive Officer Sergio Traversa said progress o
Via MarketBeat · November 13, 2026
Postmarket Movers: After-Hours Gainers and Losers for Nov. 12, 2026chartmill.com
Via Chartmill · November 12, 2026
NDV-01 Phase 2 showed 95% complete response rates, with IND filing expected by year-end.
Via The Motley Fool · August 14, 2026
Relmada Therapeutics Inc (NASDAQ:RLMD) Reports Q4 2025 Earnings Miss, Stock Declineschartmill.com
Via Chartmill · March 19, 2026
Relmada Therapeutics (NASDAQ:RLMD) said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
Chief
Via MarketBeat · August 7, 2026
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
Via Benzinga · June 18, 2026
Relmada Therapeutics (NASDAQ:RLMD) said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.
On the company’s first-q
Via MarketBeat · May 12, 2026

Relmada (RLMD) Q4 2025 Earnings Call Transcript
Via The Motley Fool · March 19, 2026
Unusual volume stocks in Tuesday's sessionchartmill.com
Via Chartmill · March 10, 2026
Top stock movements in today's session.chartmill.com
Via Chartmill · March 9, 2026
Monday's session: top gainers and loserschartmill.com
Via Chartmill · March 9, 2026
Gapping stocks in Monday's sessionchartmill.com
Via Chartmill · March 9, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · March 9, 2026
Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.
Via Stocktwits · March 9, 2026
Relmada Therapeutics posts a wider-than-expected Q3 2025 loss, but reports strong 92% response rate for its bladder cancer drug NDV-01.
Via Chartmill · November 13, 2025
Relmada (RLMD) Q3 2025 Earnings Call Transcript
Via The Motley Fool · November 13, 2025
Via Benzinga · November 4, 2025
Via Benzinga · October 6, 2025
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via Chartmill · October 3, 2025
Via Benzinga · October 3, 2025
Via Benzinga · September 4, 2025
In today's session, these stocks are experiencing unusual volume.
Via Chartmill · September 3, 2025
